These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 18574145)

  • 1. Topoisomerase levels determine chemotherapy response in vitro and in vivo.
    Burgess DJ; Doles J; Zender L; Xue W; Ma B; McCombie WR; Hannon GJ; Lowe SW; Hemann MT
    Proc Natl Acad Sci U S A; 2008 Jul; 105(26):9053-8. PubMed ID: 18574145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma.
    Wang N; Zhu M; Tsao SW; Man K; Zhang Z; Feng Y
    Mol Cancer; 2013 Oct; 12(1):119. PubMed ID: 24103454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
    Raguz S; Adams C; Masrour N; Rasul S; Papoutsoglou P; Hu Y; Cazzanelli G; Zhou Y; Patel N; Coombes C; Yagüe E
    Biochem Pharmacol; 2013 Jan; 85(2):186-96. PubMed ID: 23122841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
    Trinh BQ; Ko SY; Barengo N; Lin SY; Naora H
    Cancer Res; 2013 Jan; 73(2):1000-10. PubMed ID: 23222298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosyl-DNA phosphodiesterase inhibitors: Progress and potential.
    Laev SS; Salakhutdinov NF; Lavrik OI
    Bioorg Med Chem; 2016 Nov; 24(21):5017-5027. PubMed ID: 27687971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
    Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
    Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients.
    Heestand GM; Schwaederle M; Gatalica Z; Arguello D; Kurzrock R
    Eur J Cancer; 2017 Sep; 83():80-87. PubMed ID: 28728050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
    Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
    Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II.
    Kruczynski A; Barret JM; Van Hille B; Chansard N; Astruc J; Menon Y; Duchier C; Créancier L; Hill BT
    Clin Cancer Res; 2004 May; 10(9):3156-68. PubMed ID: 15131057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin.
    Yan T; Deng S; Metzger A; Gödtel-Armbrust U; Porter AC; Wojnowski L
    Mol Cancer Ther; 2009 May; 8(5):1075-85. PubMed ID: 19417146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride.
    Liu LM; Xiong DD; Lin P; Yang H; Dang YW; Chen G
    Int J Oncol; 2018 Nov; 53(5):1897-1912. PubMed ID: 30132517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells.
    Magan N; Isaacs RJ; Stowell KM
    Anticancer Drugs; 2012 Jul; 23(6):627-37. PubMed ID: 22293659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological characterization of MLN944: a potent DNA binding agent.
    Sappal DS; McClendon AK; Fleming JA; Thoroddsen V; Connolly K; Reimer C; Blackman RK; Bulawa CE; Osheroff N; Charlton P; Rudolph-Owen LA
    Mol Cancer Ther; 2004 Jan; 3(1):47-58. PubMed ID: 14749475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotoxic effects of topoisomerase poisoning and PARP inhibition on zebrafish embryos.
    Karapetian M; Tsikarishvili S; Kulikova N; Kurdadze A; Zaalishvili G
    DNA Repair (Amst); 2020 Mar; 87():102772. PubMed ID: 31877465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.
    Deng S; Yan T; Nikolova T; Fuhrmann D; Nemecek A; Gödtel-Armbrust U; Kaina B; Wojnowski L
    Br J Pharmacol; 2015 May; 172(9):2246-57. PubMed ID: 25521189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
    Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
    Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia.
    Saraiya B; Gounder M; Dutta J; Saleem A; Collazo C; Zimmerman L; Nazar A; Gharibo M; Schaar D; Lin Y; Shih W; Aisner J; Strair RK; Rubin EH
    Anticancer Drugs; 2008 Apr; 19(4):411-20. PubMed ID: 18454051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions.
    Williams AO; Isaacs RJ; Stowell KM
    BMC Mol Biol; 2007 May; 8():36. PubMed ID: 17511886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.
    Erriquez J; Becco P; Olivero M; Ponzone R; Maggiorotto F; Ferrero A; Scalzo MS; Canuto EM; Sapino A; Verdun di Cantogno L; Bruna P; Aglietta M; Di Renzo MF; Valabrega G
    Gynecol Oncol; 2015 Sep; 138(3):627-33. PubMed ID: 26100858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of 2,4-diaryl chromenopyridines and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
    Thapa U; Thapa P; Karki R; Yun M; Choi JH; Jahng Y; Lee E; Jeon KH; Na Y; Ha EM; Cho WJ; Kwon Y; Lee ES
    Eur J Med Chem; 2011 Aug; 46(8):3201-9. PubMed ID: 21601964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.